This is a video synopsis/summary of an Insights involving Allison Wheeler, MD. Wheeler addresses the nuanced considerations for implementing prophylaxis in patients with mild to moderate hemophilia A, ...

Gene therapy for hemophilia B allowed almost three-fourths of patients to discontinue prophylactic factor IX therapy with no increase in bleeding, results of the pivotal BENEGENE-2 trial showed. The ...

Doctors explain why preventive treatment is replacing on-demand care in haemophilia, how early prophylaxis protects joints, ...

Please provide your email address to receive an email when new articles are posted on . Patients who received prophylactic concizumab had a mean overall annualized bleeding rate of zero compared with ...

Based on initial positive results from HOPE-B, etranacogene dezaparvovec became the first gene therapy approved for adults with hemophilia B who currently use factor IX prophylaxis therapy for blood ...

The US Food and Drug Administration (FDA) has approved the gene therapy fidanacogene elaparvovec (Beqvez) for adults with hemophilia B, a rare bleeding disorder that affects almost 4 in 100,000 US men ...

The COCOON trial assessed prophylactic dermatologic regimens in NSCLC patients treated with amivantamab and lazertinib, showing reduced AEs and improved quality of life. Prophylactic treatment ...

DVT prophylaxis reduces the risk of developing deep vein thrombosis through medications, compression stockings, and devices. Deep vein thrombosis (DVT) can occur when a blood clot forms in a deep vein ...

Background. Prophylactic antimicrobial therapy is frequently prescribed for acute aspiration pneumonitis, with the intent of preventing the development of aspiration pneumonia. However, few clinical ...

The patent’s assignee is Continuous Motionflow, Llc. News editors obtained the following quote from the background information supplied by the inventors: “It is estimated that more than a million ...